Evidence from randomized screening trials in Europe shows that PSA-based screening can reduce deaths from prostate cancer (2–4), but also leads to overdiagnosis and the risk of overtreatment among elderly men with a limited life expectancy (5,6). This evidence concerns the gene KLK3 and prostate cancer.